Shop by goal

Popular compounds

GHK-Cu Copper Peptide

GLP1-RC-RT

Research resources

GLP-1s and Muscle Loss: What Lean-Mass Preservation Research Shows

Short answer: some of the weight lost on GLP-1 drugs is lean mass . In the STEP 1 DXA substudy, roughly 40% of the weight lost on semaglutide was lean mass. In the SURMOUNT-1 substudy, roughly a quarter of the weight lost on tirzepatide was. But lean mass is not the same as muscle : it also counts water, glycogen and organs. Muscle quality can even improve as fat inside the muscle falls. Researchers have stopped asking only “how much weight?” and now ask what kind of weight. That question is driving a new wave of muscle-preserving drug research.

Plain-English summary. This page explains published research. It is not medical advice. New-U Research Compounds supplies reference peptides for laboratory research only, not for human use.

Why the question changed

For years the headline number in obesity trials was percentage weight loss. Once incretin drugs started reaching 15–20% and beyond, a second question took over: how much of that is fat, and how much is everything else? When the body loses a lot of weight quickly, it does not lose only fat. The extra concern with GLP-1 drugs is scale. A larger total loss means a larger absolute lean-mass loss, even if the share is ordinary.

So “quality of weight loss” is now a trial endpoint in its own right. Drug companies are designing studies around it.

What the DXA substudies reported

Two body-composition substudies anchor most of the discussion. Both used DXA (dual-energy X-ray absorptiometry), which splits the body into fat mass, lean mass and bone.

Trial Compound Lean mass lost Lean share of weight lost STEP 1 DXA substudy Semaglutide ~6.9 kg (vs ~10.4 kg fat lost) ~40% SURMOUNT-1 DXA substudy Tirzepatide ~5.6 kg (vs ~1.2 kg lean lost on placebo) ~25%

Read the table with care. These are different trials with different people, doses and DXA protocols. They do not show that one drug is better for muscle. The head-to-head SURMOUNT-5 trial compared total weight loss, not DXA body composition, so it cannot settle the question either. In both trials, the proportion of body weight made up of lean tissue went up, because fat fell faster than lean mass.

For context, classic diet studies commonly report that around a quarter of the weight lost through calorie restriction is lean mass. The GLP-1 figures fall within the range seen with other kinds of weight loss. They do not stand clearly outside it.

Lean mass is not the same as muscle

This is the point most headlines miss. DXA “lean mass” is everything that is not fat or bone:

Skeletal muscle : the tissue people actually mean when they worry about “muscle loss”.

Water and glycogen : these fall quickly in early weight loss, and part of the first lean-mass drop is this.

Organs : the liver in particular can shrink as liver fat clears.

MRI-based work adds a second nuance. As people lose weight, the fat stored inside muscle (myosteatosis) can fall. Muscle volume may go down while the muscle that remains is of better quality. A smaller, less fatty muscle is not the same outcome as a smaller muscle that works worse.

Why researchers still take it seriously

None of this makes the question go away. Researchers focus on three groups and scenarios:

Older adults: muscle mass already declines with age, so further losses carry a higher risk for strength and mobility.

Sarcopenic obesity: people who have obesity and low muscle mass start with less reserve.

Weight cycling: after treatment stops, much of the weight tends to return. Some researchers worry that regained weight is more fat than lean, which would leave body composition worse than before. This remains an open research question.

What lean-mass preservation research measures

Newer trials go well beyond the scale. Common endpoints include:

Measure What it captures Limitation DXA Fat, lean and bone mass Lean mass includes water and organs MRI / CT Muscle volume and fat inside muscle Costly; smaller study groups Grip strength, chair-stand, gait speed Function and strength Noisy; influenced by training and effort Fat-to-lean loss ratio “Quality” of weight lost Depends on the method above

The shift toward function matters. A drug that preserves lean mass on a scan but not strength would be a weaker result than the scan suggests.

Where the research is heading

Two strands are running in parallel. The first compares body composition across incretin drugs, including the newer multi-agonists such as retatrutide vs tirzepatide. The second adds a second drug aimed at muscle to a GLP-1. Examples include bimagrumab, apitegromab and other agents that block the myostatin/activin pathway. We cover those candidates in Fat Loss Without Muscle Loss?

GLP-1 reference peptides for research

New-U Research Compounds supplies the established incretin research references:

Semaglutide : the GLP-1 receptor agonist reference.

Tirzepatide : the dual GIP/GLP-1 receptor agonist reference.

Retatrutide : the investigational GIP/GLP-1/glucagon triple-agonist reference.

Each is supplied as lyophilised reference peptide with the per-batch Certificate of Analysis published online. Research use only, not for human consumption.

Frequently Asked Questions

Do GLP-1 drugs cause muscle loss? Some of the weight lost on GLP-1 drugs is lean mass. In the STEP 1 body-composition substudy roughly 40% of the weight lost on semaglutide was lean mass, and in SURMOUNT-1 roughly a quarter of the weight lost on tirzepatide was. Lean mass is not the same as muscle, so these figures overstate pure muscle loss.

Is lean mass the same as muscle? No. DXA lean mass counts everything that is not fat or bone: skeletal muscle, organs, water and stored glycogen. Part of the early lean-mass drop during weight loss is water and glycogen rather than muscle tissue.

Is GLP-1 lean-mass loss worse than with dieting? Not clearly. Classic diet studies commonly report that around a quarter of lost weight is lean mass, which sits within the range seen in the GLP-1 trials. Cross-trial comparisons are unreliable because methods and populations differ.

Why are researchers worried about it? Muscle matters for strength, mobility and metabolic health, especially in older adults and in people who already have low muscle mass. The concern is greatest where weight loss is large and fast, and where function, not just mass, could decline.

Can New-U products preserve muscle? No. New-U Research Compounds supplies reference peptides for laboratory research only. Nothing on this site is a treatment, and no compound here is for human use.

Primary sources & further reading

Wilding JPH et al. — Once-weekly semaglutide in adults with overweight or obesity (STEP 1), NEJM 2021

Jastreboff AM et al. — Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), NEJM 2022

U.S. National Library of Medicine — PubMed: GLP-1 receptor agonists, lean mass and body composition

ClinicalTrials.gov — registered lean-mass preservation trials

External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way.

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified Incretin Research References

New-U Research Compounds catalogues semaglutide, tirzepatide and retatrutide as lyophilised reference peptides, with the per-batch Certificate of Analysis published online. Research use only - all claims made on this site are for testing and research use only.

Research-grade · >99% HPLC purity · COA per lot

Buy research peptides from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. Research use only - all claims made on this site are for testing and research use only.

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research